David G. Maloney
Matching-adjusted indirect treatment comparison of liso-cel versus axi-cel in relapsed or refractory large B cell lymphoma
Maloney, David G.; Kuruvilla, John; Liu, Fei Fei; Kostic, Ana; Kim, Yeonhee; Bonner, Ashley; Zhang, Yixie; Fox, Christopher P.; Cartron, Guillaume
Authors
John Kuruvilla
Fei Fei Liu
Ana Kostic
Yeonhee Kim
Ashley Bonner
Yixie Zhang
Professor CHRIS FOX Christopher.Fox@nottingham.ac.uk
Clinical Professor in Haematology
Guillaume Cartron
Abstract
Background: In the absence of randomized studies directly comparing chimeric antigen receptor T cell therapies, this study used matching-adjusted indirect comparisons (MAIC) to evaluate the comparative efficacy and safety of lisocabtagene maraleucel (liso-cel) versus axicabtagene ciloleucel (axi-cel) in patients with relapsed or refractory large B cell lymphoma (LBCL). Methods: Primary data sources included individual patient data from the TRANSCEND NHL 001 study (TRANSCEND [NCT02631044]; N = 256 for efficacy set, N = 269 for safety set) for liso-cel and summary-level data from the ZUMA-1 study (NCT02348216; N = 101 for efficacy set, N = 108 for safety set) for axi-cel. Inter-study differences in design, eligibility criteria, baseline characteristics, and outcomes were assessed and aligned to the extent feasible. Clinically relevant prognostic factors were adjusted in a stepwise fashion by ranked order. Since bridging therapy was allowed in TRANSCEND but not ZUMA-1, the initial efficacy and safety analyses included bridging therapy use as a matching factor (TRANSCEND patients who received bridging therapy were removed). Subsequent sensitivity analyses excluded this matching factor. Results: The initial analysis showed similar MAIC-weighted efficacy outcomes between TRANSCEND and ZUMA-1 for overall and complete response rates (odds ratio [95% confidence interval (CI)], 1.40 [0.56–3.49] and 1.21 [0.56–2.64], respectively) and for overall survival and progression-free survival (hazard ratio [95% CI], 0.81 [0.44–1.49] and 0.95 [0.58–1.57], respectively). MAIC-weighted safety outcomes favored liso-cel, with significantly lower odds of all-grade and grade ≥ 3 cytokine release syndrome (odds ratio [95% CI], 0.03 [0.01–0.07] and 0.08 [0.01–0.67], respectively) and study-specific neurological events (0.16 [0.08–0.33] and 0.05 [0.02–0.15], respectively). Efficacy and safety outcomes remained similar in sensitivity analyses, which did not include use of bridging therapy as a matching factor. Conclusions: After matching and adjusting for clinically relevant prognostic factors, liso-cel demonstrated comparable efficacy and a more favorable safety profile compared with axi-cel in patients with third- or later-line relapsed or refractory LBCL. Trial registration: NCT02631044 and NCT02348216
Citation
Maloney, D. G., Kuruvilla, J., Liu, F. F., Kostic, A., Kim, Y., Bonner, A., …Cartron, G. (2021). Matching-adjusted indirect treatment comparison of liso-cel versus axi-cel in relapsed or refractory large B cell lymphoma. Journal of Hematology and Oncology, 14(1), Article 140. https://doi.org/10.1186/s13045-021-01144-9
Journal Article Type | Article |
---|---|
Acceptance Date | Aug 21, 2021 |
Online Publication Date | Sep 8, 2021 |
Publication Date | Sep 8, 2021 |
Deposit Date | Feb 8, 2023 |
Publicly Available Date | Feb 8, 2023 |
Journal | Journal of Hematology & Oncology |
Print ISSN | 1756-8722 |
Electronic ISSN | 1756-8722 |
Publisher | BioMed Central |
Peer Reviewed | Peer Reviewed |
Volume | 14 |
Issue | 1 |
Article Number | 140 |
DOI | https://doi.org/10.1186/s13045-021-01144-9 |
Keywords | Cancer Research; Oncology; Molecular Biology; Hematology |
Public URL | https://nottingham-repository.worktribe.com/output/17078658 |
Publisher URL | https://jhoonline.biomedcentral.com/articles/10.1186/s13045-021-01144-9 |
Files
Matching-adjusted indirect treatment comparison of liso-cel versus axi-cel in relapsed or refractory large B cell lymphoma
(1.4 Mb)
PDF
Publisher Licence URL
https://creativecommons.org/licenses/by/4.0/
You might also like
Risk-stratified monitoring for sulfasalazine toxicity: prognostic model development and validation
(2023)
Preprint / Working Paper
Downloadable Citations
About Repository@Nottingham
Administrator e-mail: discovery-access-systems@nottingham.ac.uk
This application uses the following open-source libraries:
SheetJS Community Edition
Apache License Version 2.0 (http://www.apache.org/licenses/)
PDF.js
Apache License Version 2.0 (http://www.apache.org/licenses/)
Font Awesome
SIL OFL 1.1 (http://scripts.sil.org/OFL)
MIT License (http://opensource.org/licenses/mit-license.html)
CC BY 3.0 ( http://creativecommons.org/licenses/by/3.0/)
Powered by Worktribe © 2024
Advanced Search